<DOC>
	<DOC>NCT00088790</DOC>
	<brief_summary>Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.</brief_summary>
	<brief_title>AZD5438 in Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<criteria>Advanced solid malignancy Cancer refractory to standard treatments or for which no standard therapy exits Radiotherapy within 3 weeks of the start of treatment Investigational product within the last 3 weeks Systemic cytotoxic anticancer therapy within the last 3 weeks Any significant clinical disorder that makes it undesirable for the patient to participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>advanced, solid, malignancies</keyword>
</DOC>